Cargando…

Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study

BACKGROUND: Bone is the most common metastatic site of breast cancer. The developmental pattern of bone metastasis differs in different molecular subtypes. The prognostic factors of HER2‐positive breast cancer with bone metastases require further investigation. The goal of this retrospective study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Xiaoshuang, Luo, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607243/
https://www.ncbi.nlm.nih.gov/pubmed/34612593
http://dx.doi.org/10.1002/cam4.4326
_version_ 1784602523524399104
author Lyu, Xiaoshuang
Luo, Bin
author_facet Lyu, Xiaoshuang
Luo, Bin
author_sort Lyu, Xiaoshuang
collection PubMed
description BACKGROUND: Bone is the most common metastatic site of breast cancer. The developmental pattern of bone metastasis differs in different molecular subtypes. The prognostic factors of HER2‐positive breast cancer with bone metastases require further investigation. The goal of this retrospective study was to identify the clinical features and prognostic factors for HER2‐positive patients with bone metastases. METHODS: A total of 34,084 HER2‐positive breast cancer cases and 1204 cases of bone metastases from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 were analyzed to identify clinical characteristics and prognostic factors. A nomogram was constructed based on the Cox proportional hazards regression model. The C‐index, calibration curve, and receiver operating characteristic (ROC) were utilized for model validation. RESULTS: In the HER2‐positive breast cancer total population (34,084 cases), 6.2% developed metastatic diseases. Bone metastases accounted for 3.5% of the entire cohort and 56.7% of all metastatic cases. Univariate and multivariate Cox regression analyses identified seven prognostic factors for predicting cancer‐specific survival (CSS) for HER2‐positive breast cancer patients with bone metastases, including age, brain metastases, liver metastases, lung metastases, PR status, surgery, and chemotherapy. The C‐index of the nomogram was 0.74 vs. 0.78 (for 3‐year CSS) and 0.77 vs. 0.81 (for 5‐year CSS) in the model and validation cohorts, respectively. The AUCs were 0.74 vs. 0.78 (for 3‐year CSS) and 0.77 vs. 0.81 (for 5‐year CSS) in the model and validation cohorts, respectively. The calibration curves indicated favorable agreement between the actual observations and the predictions. CONCLUSION: Our study provided population‐based clinical features and prognostic factors for HER2‐positive breast cancer patients with bone metastases and we constructed a prognostic nomogram with reliable accuracy.
format Online
Article
Text
id pubmed-8607243
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86072432021-11-29 Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study Lyu, Xiaoshuang Luo, Bin Cancer Med Clinical Cancer Research BACKGROUND: Bone is the most common metastatic site of breast cancer. The developmental pattern of bone metastasis differs in different molecular subtypes. The prognostic factors of HER2‐positive breast cancer with bone metastases require further investigation. The goal of this retrospective study was to identify the clinical features and prognostic factors for HER2‐positive patients with bone metastases. METHODS: A total of 34,084 HER2‐positive breast cancer cases and 1204 cases of bone metastases from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 were analyzed to identify clinical characteristics and prognostic factors. A nomogram was constructed based on the Cox proportional hazards regression model. The C‐index, calibration curve, and receiver operating characteristic (ROC) were utilized for model validation. RESULTS: In the HER2‐positive breast cancer total population (34,084 cases), 6.2% developed metastatic diseases. Bone metastases accounted for 3.5% of the entire cohort and 56.7% of all metastatic cases. Univariate and multivariate Cox regression analyses identified seven prognostic factors for predicting cancer‐specific survival (CSS) for HER2‐positive breast cancer patients with bone metastases, including age, brain metastases, liver metastases, lung metastases, PR status, surgery, and chemotherapy. The C‐index of the nomogram was 0.74 vs. 0.78 (for 3‐year CSS) and 0.77 vs. 0.81 (for 5‐year CSS) in the model and validation cohorts, respectively. The AUCs were 0.74 vs. 0.78 (for 3‐year CSS) and 0.77 vs. 0.81 (for 5‐year CSS) in the model and validation cohorts, respectively. The calibration curves indicated favorable agreement between the actual observations and the predictions. CONCLUSION: Our study provided population‐based clinical features and prognostic factors for HER2‐positive breast cancer patients with bone metastases and we constructed a prognostic nomogram with reliable accuracy. John Wiley and Sons Inc. 2021-10-06 /pmc/articles/PMC8607243/ /pubmed/34612593 http://dx.doi.org/10.1002/cam4.4326 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Lyu, Xiaoshuang
Luo, Bin
Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
title Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
title_full Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
title_fullStr Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
title_full_unstemmed Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
title_short Prognostic factors and survival prediction in HER2‐positive breast cancer with bone metastases: A retrospective cohort study
title_sort prognostic factors and survival prediction in her2‐positive breast cancer with bone metastases: a retrospective cohort study
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607243/
https://www.ncbi.nlm.nih.gov/pubmed/34612593
http://dx.doi.org/10.1002/cam4.4326
work_keys_str_mv AT lyuxiaoshuang prognosticfactorsandsurvivalpredictioninher2positivebreastcancerwithbonemetastasesaretrospectivecohortstudy
AT luobin prognosticfactorsandsurvivalpredictioninher2positivebreastcancerwithbonemetastasesaretrospectivecohortstudy